DaVita Inc.

NYSE:DVA Stock Report

Market Cap: US$13.5b

DaVita Valuation

Is DVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$387.46
Fair Value
57.1% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: DVA ($166.24) is trading below our estimate of fair value ($387.46)

Significantly Below Fair Value: DVA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DVA?

Key metric: As DVA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DVA. This is calculated by dividing DVA's market cap by their current earnings.
What is DVA's PE Ratio?
PE Ratio16.5x
EarningsUS$827.68m
Market CapUS$13.52b

Price to Earnings Ratio vs Peers

How does DVA's PE Ratio compare to its peers?

The above table shows the PE ratio for DVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.5x
CHE Chemed
27.4x8.8%US$8.3b
DGX Quest Diagnostics
20.1x11.7%US$16.9b
LH Labcorp Holdings
45.8x22.4%US$20.0b
CRVL CorVel
68.6xn/aUS$5.6b
DVA DaVita
16.5x3.4%US$13.5b

Price-To-Earnings vs Peers: DVA is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (40.5x).

Price to Earnings Ratio vs Industry

How does DVA's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
4x-30.2%US$12.63b
NEUE NeueHealth
2.2xn/aUS$60.83m
IDXG Interpace Biosciences
0.8xn/aUS$4.05m
No more companies available in this PE range
DVA 16.5xIndustry Avg. 22.8xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DVA is good value based on its Price-To-Earnings Ratio (16.5x) compared to the US Healthcare industry average (22.8x).

Price to Earnings Ratio vs Fair Ratio

What is DVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.5x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: DVA is good value based on its Price-To-Earnings Ratio (16.5x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DVA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$166.24
US$156.93
-5.6%
10.1%US$186.00US$134.00n/a9
Jan ’26US$149.55
US$156.93
+4.9%
10.1%US$186.00US$134.00n/a9
Dec ’25US$166.17
US$156.90
-5.6%
10.1%US$186.00US$134.00n/a9
Nov ’25US$141.59
US$157.46
+11.2%
10.4%US$186.00US$134.00n/a9
Oct ’25US$162.75
US$153.13
-5.9%
8.0%US$175.00US$134.00n/a8
Sep ’25US$150.92
US$148.44
-1.6%
10.2%US$175.00US$123.50n/a8
Aug ’25US$137.52
US$143.56
+4.4%
10.0%US$169.00US$122.00n/a8
Jul ’25US$138.61
US$142.19
+2.6%
10.0%US$169.00US$122.00n/a8
Jun ’25US$147.12
US$142.19
-3.4%
10.0%US$169.00US$122.00n/a8
May ’25US$139.75
US$130.59
-6.6%
5.9%US$145.00US$119.80n/a9
Apr ’25US$137.84
US$130.59
-5.3%
5.9%US$145.00US$119.80n/a9
Mar ’25US$126.92
US$128.41
+1.2%
6.7%US$145.00US$119.80n/a8
Feb ’25US$112.23
US$108.38
-3.4%
8.6%US$120.00US$90.00n/a8
Jan ’25US$104.76
US$105.38
+0.6%
7.2%US$115.00US$90.00US$149.558
Dec ’24US$104.31
US$104.38
+0.06%
6.5%US$113.00US$90.00US$166.178
Nov ’24US$77.44
US$110.88
+43.2%
11.2%US$142.00US$100.00US$141.598
Oct ’24US$94.53
US$113.75
+20.3%
10.4%US$142.00US$100.00US$162.758
Sep ’24US$102.99
US$114.25
+10.9%
10.1%US$142.00US$100.00US$150.928
Aug ’24US$102.39
US$104.88
+2.4%
6.5%US$115.00US$96.00US$137.528
Jul ’24US$100.47
US$103.00
+2.5%
5.6%US$113.00US$96.00US$138.618
Jun ’24US$94.71
US$99.99
+5.6%
7.8%US$113.00US$84.90US$147.128
May ’24US$90.39
US$90.36
-0.03%
7.8%US$108.00US$84.90US$139.758
Apr ’24US$81.11
US$88.24
+8.8%
10.0%US$108.00US$74.00US$137.848
Mar ’24US$82.33
US$88.83
+7.9%
11.4%US$108.00US$74.00US$126.926
Feb ’24US$84.81
US$82.33
-2.9%
14.7%US$108.00US$72.00US$112.236
Jan ’24US$74.67
US$80.83
+8.3%
15.3%US$108.00US$72.00US$104.766
Analyst Price Target
Consensus Narrative from 9 Analysts
US$156.93
Fair Value
5.9% overvalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 22:52
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DaVita Inc. is covered by 37 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stephan GasteygerAtlantic Equities LLP
Brian WilliamsAvondale Partners
Matthew GillmorBaird